Welcome in the research database

The antiphospholipid antibody syndrome (APS)

The antiphospholipid antibody syndrome (APS) is characterized by clinical manifestations such as arterial or venous thromboembolism and recurrent pregnancy loss as well as the presence of antiphospholipid antibodies (aPLA). Inflammatory activation of the vascular endothelium appears to be a major pathogenic mechanism by which aPLA induce the thrombophilic state observed in APS. The study of APS is complicated by the polyclonal nature of aPLA, the variety of putative target antigens, the heterogeneity of the mechanisms proposed for endothelial cell activation, and the moderate concordance between aPLA detection assays.

Recent studies performed by our group and elsewhere provided evidence that one (or more) members of the Toll-like receptor (TLR) family mediate the cellular response to aPLA. TLRs are cell surface receptors that recognize pathogen associated molecular patterns and constitute a first line of defence by launching an inflammatory response against bacteria and viruses. TLRs have also been implicated in several autoimmune disorders and in atherosclerosis. Our aim is to better characterize the role of TLRs in APS which may improve our understanding of the pathogenic mechanisms leading to APS and facilitate the development of new therapeutic approaches for the treatment of APS.

Group's publications

Anticoagulants in portal vein thrombosis: don't be so shy!
BLOOD
2009 vol. 113(20) pp. 5031-5032
SPAHR L, BOEHLEN F, DE MOERLOOSE P, HADENGUE A

A novel frameshift mutation in FGA accounting for congenital afibrinogenemia predicted to encode an aberrant peptide terminating 158 amino acids downstream.
BLOOD COAGULATION AND FIBRINOLYSIS
2009 vol. 20(5) pp. 385-387
ROBERT-EBADI H, DE MOERLOOSE P, EL KHORASSANI M, EL KHATTAB M, NEERMAN-ARBEZ M

Severe bleeding and miscarriages in a hypofibrinogenemic woman heterozygous for the gamma Ala82Gly mutation
BLOOD COAGULATION AND FIBRINOLYSIS
2009 vol. 20(5) pp. 374-376
ZDZIARSKA J, UNDAS A, BASA J, IWANIEC T, SKOTNICKI AB, DE MOERLOOSE P, NEERMAN-ARBEZ M

European curriculum for thrombosis and haemostasis.
HAEMOPHILIA
2009 vol. 15(1) pp. 337-344
ASTERMARK J AND AL.

Replacement therapy for invasive procedures in patients with haemophilia: literature review European survey and recommendations
HAEMOPHILIA
2009 vol. 15(3) pp. 639-658
HERMANS C AND AL.

Evaluation of a new quantitative highly sensitive D-dimer assay for exclusion of venous thromboembolism.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
2009 vol. 7(9) pp. 1590-1591
DE MOERLOOSE P, REBER G, ARNOUT J

Platelet hyperreactivity and dual antiplatelet therapy: can biases be avoided?
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
2009 vol. 7(2) pp. 363-364
FONTANA P, DE MOERLOOSE P, RENY JL

The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
2009 vol. 7(11) pp. 1767-1773
DE LAAT B AND AL.

[The concept of aspirin "resistance": mechanisms and clinical relevance].
REVUE DE MEDECINE INTERNE
2009 vol. 30(12) pp. 1020-1029
RENY JL, BONVINI R, BARAZER I, BERDAGUE P, DE MOERLOOSE P, SCHVED JF, GRIS JC, FONTANA P

Congenital fibrinogen disorders.
SEMINARS IN THROMBOSIS AND HEMOSTASIS
2009 vol. 35(4) pp. 356-366
DE MOERLOOSE P, NEERMAN-ARBEZ M

Diagnosis of mild bleeding disorders.
SWISS MEDICAL WEEKLY
2009 vol. 139(23-24) pp. 327-332
DE MOERLOOSE P, LEVRAT E, FONTANA P, BOEHLEN F

Anti-beta(2)-glycoprotein I ELISA assay: the influence of different antigen preparations.
THROMBOSIS AND HAEMOSTASIS
2009 vol. 101(4) pp. 789-791
CAVAZZANA A, PENGO V, TONELLO M, NOVENTA F, GROSSI C, BORGHI MO, DE MOERLOOSE P, REBER G, RUFFATTI A

Fibrinogen Krakow: A novel hypo/dysfibrinogenemia mutation in fibrinogen gamma chain (Asn325IIe) affecting fibrin clot structure and function
THROMBOSIS AND HAEMOSTASIS
2009 vol. 101(5) pp. 975-976
UNDAS A, ZDZIARSKA J, IWANIEC T, STEPIEN E, SKOTNICKI AB, DE MOERLOOSE P, NEERMAN-ARBEZ M

Deletion of 3 residues from the C-terminus of MCFD2 affects binding to ERGIC-53 and causes combined factor V and factor VIII deficiency.
BLOOD
2008 vol. 111(3) pp. 1299-1301
NYFELER B, KAMIYA, BOEHLEN F, YAMAMOTO K, KATO K, DE MOERLOOSE P, HAURI HP, NEERMAN-ARBEZ M

A novel Asp344Val substitution in the fibrinogen gamma chain (fibrinogen Caen) causes dysfibrinogenemia associated with thrombosis.
BLOOD COAGULATION AND FIBRINOLYSIS
2008 vol. 19(7) pp. 697-699
ROBERT-EBADI H, LE QUERREC A, DE MOERLOOSE P, GANDON-LALOUM S, BOREL DERLON A, NEERMAN-ARBEZ M

Treatment of congenital fibrinogen disorders.
EXPERT OPINION ON BIOLOGICAL THERAPY
2008 vol. 8(7) pp. 979-992
DE MOERLOOSE P, NEERMAN-ARBEZ M

Endothelial cell activation by immunoglobulins from patients with immune thrombocytopenic purpura or with antiphospholipid syndrome.
HAEMATOLOGIA
2008 vol. 93(4) pp. 635-636
DUNOYER-GEINDRE S, BOEHLEN F, FAVIER R, WAHL D, MUSIAL J, KORTE W, SATTA N, KRUITHOF EGBERT, DE MOERLOOSE P

A survey of adherence to haemophilia therapy in six European countries: results and recommendations.
HAEMOPHILIA
2008 vol. 14(5) pp. 931-938
DE MOERLOOSE P, URBANCIK W, VAN DEN BERG HM, RICHARDS M

Molecular analysis of F8 in Lebanese haemophilia A patients: novel mutations and phenotype-genotype correlation.
HAEMOPHILIA
2008 vol. 14(4) pp. 709-716
DJAMBAS KHAYAT C, SALEM N, CHOUERY E, CORBANI S, MOIX I, NICOLAS I, MORRIS M, DE MOERLOOSE P, MEGARBANE A

Rare bleeding disorders.
HAEMOPHILIA
2008 vol. 14 pp. 202-210
PEYVANDI F, CATTANEO M, INBAL A, DE MOERLOOSE P, SPREAFICO M

Richards M
HAEMOPHILIA
2008 vol. 14(4) pp. 709-716
DJAMBAS KHAYAT C, SALEM N, CHOUERY E, CORBANI S, MOIX I, NICOLAS E, MORRIS MA, DE MOERLOOSE P, MÉGARBANÉ A

D-Dimer for venous thromboembolism diagnosis: 20 years later.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
2008 vol. 6(7) pp. 1059-1071
RIGHINI M, PERRIER A, DE MOERLOOSE P, BOUNAMEAUX H

Invitation to a debate on the serological criteria that define the antiphospholipid syndrome.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
2008 vol. 6(2) pp. 399-401
GALLI M, REBER G, DE MOERLOOSE P, DE GROOT PG

Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
2008 vol. 6(3) pp. 444-450
RENY JL, DE MOERLOOSE P, DAUZAT M, FONTANA P

Induction of TLR2 expression by inflammatory stimuli is required for endothelial cell responses to lipopeptides.
MOLECULAR IMMUNOLOGY
2008 vol. 46(1) pp. 145-157
SATTA N, KRUITHOF EK, REBER G, DE MOERLOOSE P

Technical aspects in laboratory testing for antiphospholipid antibodies: is standardization an impossible dream?
SEMINARS IN THROMBOSIS AND HEMOSTASIS
2008 vol. 34(4) pp. 340-346
REBER G, BOEHLEN F, DE MOERLOOSE P

A multicenter evaluation of a new quantitative highly sensitive D-dimer assay for exclusion of venous thromboembolism.
THROMBOSIS AND HAEMOSTASIS
2008 vol. 100(3) pp. 505-512
DE MOERLOOSE P, PALARETI G, AGUILAR C, LEGNANI C, REBER G, PEETZ D

Aspirin response variability assessed with the PFA-100 device.
THROMBOSIS AND HAEMOSTASIS
2008 vol. 99(5) pp. 968-969
RENY JL, QUÉRÉ I, DE MOERLOOSE P, FONTANA P

Assessing aspirin responsiveness using the Verify Now Aspirin assay.
THROMBOSIS RESEARCH
2008 vol. 121(4) pp. 581-582
FONTANA P, REBER G, DE MOERLOOSE P

Preventing and treating bleeding complications: new insights into therapeutic options.
THROMBOSIS RESEARCH
2008 vol. 122 pp. 1-2
DE MOERLOOSE P, NEGRIER C

An analysis of experimental conditions influencing the anti-beta2-glycoprotein I ELISA assay results
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
2007 vol. 1109 pp. 484-492
CAVAZZANA A, RUFFATTI A, TONELLO M, BORTOLATI M, DE MOERLOOSE P, REBER G

The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies
BLOOD
2007 vol. 109 pp. 1507-1514
SATTA N, DUNOYER-GEINDRE S, REBER G, FISH RJ, BOEHLEN F, KRUITHOF EKO, DE MOERLOOSE P

Platelet refractoriness due to combined anti-HLA and anti-HPA-5a alloantibodies: clinical management during myeloablative allogeneic HSCT and development of a quantitative MAIPA assay
BRITISH JOURNAL OF HAEMATOLOGY
2007 vol. 139 pp. 159-161
ARBER C, BERTRAND G, HALTER J, BOEHLEN F, KAPLAN C, GRATWOHL A

Heparin-induced thrombocytopenia associated with interleukin-8-dependent platelet activation in a patient with antiphospholipid syndrome
EUROPEAN JOURNAL OF HAEMATOLOGY
2007 vol. 79 pp. 550-553
BOUNAMEAUX C, BOEHLEN F, MEMBRE A, GENNE D, POUPLARD C, REGNAULT V, DE MOERLOOSE P

Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data
HAEMOPHILIA
2007 vol. 13 pp. 473-479
RICHARDS M, ALTISENT C, BATOROVA A, CHAMBOST H, DOLAN G, DE MOERLOOSE P, FRAGA M, HERMANS C, KARAFOULIDOU A, KLAMROTH R, LASSILA R, ROTHSCHILD C

Mutations in the fibrinogen gene cluster accounting for congenital afibrinogenemia: An update and report of 10 novel mutations
HUMAN MUTATION
2007 vol. 28 pp. 540-553
NEERMAN-ARBEZ, M, DE MOERLOOSE, P

Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
2007 vol. 5 pp. 2153-2155
FONTANA P, HULOT JS, DE MOERLOOSE P, GAUSSEM P

Performance of the AxSYM (R) D-dimer assay for the exclusion of pulmonary embolism
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
2007 vol. 5 pp. 2304-2305
REBER G, BOEHLEN F, BOUNAMEAUX H, DE MOERLOOSE P

Inherited thrombophilia in arterial disease: A selective review
SEMINARS IN HEMATOLOGY
2007 vol. 44 pp. 106-113
DE MOERLOOSE P, BOEHLEN F

Immunization of LDL receptor-deficient mice with beta(2)-glycoprotein 1 or human serum albumin induces a more inflammatory phenotype in atherosclerotic plaques
THROMBOSIS AND HAEMOSTASIS
2007 vol. 97 pp. 129-138
DUNOYER-GEINDRE S, KWAK BR, PELLI G, ROTH I, SATTA N, FISH RJ, REBER G, MACH F, KRUITHOF EKO, DE MOERLOOSE P

Management of venous thromboembolism
CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE
2006 vol. 53(6 Suppl) pp. 80-88
DE MOERLOOSE P, SAMAMA CM, MOTTE S

Minimizing perioperative blood loss and transfusions in children
CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE
2006 vol. 53 pp. 59-67
GUAY J, DE MOERLOOSE P, LASNE D

Point of care management of heparin administration after heart surgery - A randomized, controlled trial
INTENSIVE CARE MEDICINE
2006 vol. 32 pp. 1357-1364
MERLANI PG, CHENAUD C, COTTINI S, REBER G, GARNERIN P, DE MOERLOOSE P, RICOU B

Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
2006 vol. 4 pp. 813-819
FONTANA P, NOLLI S, REBER G, DE MOERLOOSE P

A model for the harmonisation of test results of different quantitative D-dimer methods
THROMBOSIS AND HAEMOSTASIS
2006 vol. 95 pp. 567-572
MEIJER P, HAVERKATE F, KLUFT C, DE MOERLOOSE P, VERBRUGGEN B, SPANNAGL M

Combined factorV-factorVIII deficiency (F5F8D): Compound heterozygosity for two novel truncating mutations in LMANI in a consanguineous patient
THROMBOSIS AND HAEMOSTASIS
2006 vol. 95 pp. 893-895
FARAH RA, DE MOERLOOSE P, BOUCHARDY I, MORRIS MA, BARAKAT W, SAYAD AE, NEERMAN-ARBEZ M

Discrepancy between capillary and venous International Normalised Ratio (INR) in a patient on vitamin-K antagonist: Potentially serious clinical consequences
THROMBOSIS AND HAEMOSTASIS
2006 vol. 96 pp. 688-689
ABRAMOWSKI SW, BOEHLEN F, REBER G, DE MOERLOOSE P

Extensive thromboembolic event as initial presentation of monoclonal gammopathy of undetermined significance
THROMBOSIS AND HAEMOSTASIS
2006 vol. 96 pp. 93-94
RIGHINI M, BOEHLEN F, GUEDDI S, LE GAL G, DE MOERLOOSE P

Massive transfusion and coagulopathy: pathophysiology and implications for clinical management
CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE
2004 vol. 51 pp. 293-310
HARDY JF, DE MOERLOOSE PHILIPPE, SAMAMA M

End-stage liver disease in person with hemophilia and transfusion-associated infections
BLOOD
2002 vol. 100 pp. 1584-1589
GOEDERT J, EYSTER E, LEDERMAN M, MANDALAKI T, DE MOERLOOSE P, WHITE GC, ANGIOLILLO AL, LUBAN NLC, SHERMAN KE, MANCO-JOHNSON M, PREISS L, LEISSINGER C, KESSLER CM, COHEN AR, DIMICHELE D, HILGARTNER MW, ALEDORT LM, KRONER BL, ROSENBERG PS, HATZAKIS A

Inherited factor VII deficiency and surgery : clinical data are the best criteria to predict the risk of bleeding
BRITISH JOURNAL OF HAEMATOLOGY
2002 vol. 117 pp. 172-175
GIANSILY-BLAIZOT M, BIRON-ANDREANI C, AGUILAR-MARTINEZ P, DE MOERLOOSE P, BRIQUEL ME, GOUDEMAND J, STIELTJES N, BARROT C, CHAMBOST H, DURIN A, GAY V, PEYNET J, POYMAYOU K, SCHVED JF

Two new antithrombotic agents (fondaparinux and ximelagatran) and their implications in anesthesia
CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE
2002 vol. 49 pp. 5-10
DE MOERLOOSE P, BOEHLEN F

Aerosolized iloprost induces a mild but sustained inhibition of platelet aggregation
EUROPEAN RESPIRATORY JOURNAL
2002 vol. 19 pp. 518-524
BEGHETTI M, REBER G, DE MOERLOOSE P, VADAS L, CHIAPPE A, SPAHR-SCHOPFER I, RIMENSBERGER PC

Measurement of red blood cell methylfolate
LANCET
2002 vol. 360 pp. 1021-1022
QUERE I, ZITTOUN J, GRIS JC, JANBON C, DE MOERLOOSE P

Red blood cell methylfolate and plasma homocysteine as risk factors for venous thromboembolism: a matched case-control study
LANCET
2002 vol. 359 pp. 747-752
QUÉRÉ I, PERNEGER TV, ZITTOUN J, BELLET H, GRIS JC, DAURES JP, SCHVED JF, MERCIER E, LAROCHE JP, DAUZAT M, BOUNAMEAUX H, JANBON C, DE MOERLOOSE P

Pelvic haemophilic pseudotumor: management of a patient with high level of inhibitors
SKELETAL RADIOLOGY
2002 vol. 31 pp. 550-553
KELLER A, TERRIER F, SCHNEIDER PA, BIANCHI S, HOWARTH N, DE MOERLOOSE P

Inter-variability of anti-b2glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group.
THROMBOSIS AND HAEMOSTASIS
2002 vol. 88 pp. 66-73
REBER G, SHOESBOE I, TINCANI A, SANMARCO M, KVEDER T, DE MOERLOOSE P, BOFFA MC, ARVIEUX J

NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies
THROMBOSIS AND HAEMOSTASIS
2002 vol. 88 pp. 851-857
DUNOYER-GEINDRE S, DE MOERLOOSE P, GALVE-DE ROCHEMONTEIX B, REBER G, KRUITHOF EK

Evaluation of Advanced D-dimer assay for the exclusion of venous thromboembolism
THROMBOSIS RESEARCH
2002 vol. 107 pp. 197-200
REBER G, BOUNAMEAUX H, PERRIER A, DE MOERLOOSE P

Point of care and central laboratory determinations of the aPTT are not interchangeable in surgical intensive care patients
CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE
2001 vol. 48 pp. 1155-1160
FERRING M, REBER G, DE MOERLOOSE P, MERLANI P, DIBY M, RICOU B

Research's domains




DATABASE-RESEARCH	GROUP OF CLINICAL PATIENT RESEARCH

Philippe DE MOERLOOSE	Head of group CV	Research subject	Members of the group


	Links about the group Pr. Ph. de MOERLOOSE HUG/Spécialités de médecine Service d'Angiologie Hémostase Rue Gabrielle-Perret-Gentil 4 1211 Genève 14 Suisse Philippe.DeMoerloose@unige.ch Tel.: 022/372.97.51 Fax: 022/372.97.77 Comments Pages updated the 17.11.2015		Reseach's subject \| Group's publications \| Research's domains The antiphospholipid antibody syndrome (APS) The antiphospholipid antibody syndrome (APS) is characterized by clinical manifestations such as arterial or venous thromboembolism and recurrent pregnancy loss as well as the presence of antiphospholipid antibodies (aPLA). Inflammatory activation of the vascular endothelium appears to be a major pathogenic mechanism by which aPLA induce the thrombophilic state observed in APS. The study of APS is complicated by the polyclonal nature of aPLA, the variety of putative target antigens, the heterogeneity of the mechanisms proposed for endothelial cell activation, and the moderate concordance between aPLA detection assays. Recent studies performed by our group and elsewhere provided evidence that one (or more) members of the Toll-like receptor (TLR) family mediate the cellular response to aPLA. TLRs are cell surface receptors that recognize pathogen associated molecular patterns and constitute a first line of defence by launching an inflammatory response against bacteria and viruses. TLRs have also been implicated in several autoimmune disorders and in atherosclerosis. Our aim is to better characterize the role of TLRs in APS which may improve our understanding of the pathogenic mechanisms leading to APS and facilitate the development of new therapeutic approaches for the treatment of APS. Group's publications Anticoagulants in portal vein thrombosis: don't be so shy! BLOOD 2009 vol. 113(20) pp. 5031-5032 SPAHR L, BOEHLEN F, DE MOERLOOSE P, HADENGUE A A novel frameshift mutation in FGA accounting for congenital afibrinogenemia predicted to encode an aberrant peptide terminating 158 amino acids downstream. BLOOD COAGULATION AND FIBRINOLYSIS 2009 vol. 20(5) pp. 385-387 ROBERT-EBADI H, DE MOERLOOSE P, EL KHORASSANI M, EL KHATTAB M, NEERMAN-ARBEZ M Severe bleeding and miscarriages in a hypofibrinogenemic woman heterozygous for the gamma Ala82Gly mutation BLOOD COAGULATION AND FIBRINOLYSIS 2009 vol. 20(5) pp. 374-376 ZDZIARSKA J, UNDAS A, BASA J, IWANIEC T, SKOTNICKI AB, DE MOERLOOSE P, NEERMAN-ARBEZ M European curriculum for thrombosis and haemostasis. HAEMOPHILIA 2009 vol. 15(1) pp. 337-344 ASTERMARK J AND AL. Replacement therapy for invasive procedures in patients with haemophilia: literature review European survey and recommendations HAEMOPHILIA 2009 vol. 15(3) pp. 639-658 HERMANS C AND AL. Evaluation of a new quantitative highly sensitive D-dimer assay for exclusion of venous thromboembolism. JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2009 vol. 7(9) pp. 1590-1591 DE MOERLOOSE P, REBER G, ARNOUT J Platelet hyperreactivity and dual antiplatelet therapy: can biases be avoided? JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2009 vol. 7(2) pp. 363-364 FONTANA P, DE MOERLOOSE P, RENY JL The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2009 vol. 7(11) pp. 1767-1773 DE LAAT B AND AL. [The concept of aspirin "resistance": mechanisms and clinical relevance]. REVUE DE MEDECINE INTERNE 2009 vol. 30(12) pp. 1020-1029 RENY JL, BONVINI R, BARAZER I, BERDAGUE P, DE MOERLOOSE P, SCHVED JF, GRIS JC, FONTANA P Congenital fibrinogen disorders. SEMINARS IN THROMBOSIS AND HEMOSTASIS 2009 vol. 35(4) pp. 356-366 DE MOERLOOSE P, NEERMAN-ARBEZ M Diagnosis of mild bleeding disorders. SWISS MEDICAL WEEKLY 2009 vol. 139(23-24) pp. 327-332 DE MOERLOOSE P, LEVRAT E, FONTANA P, BOEHLEN F Anti-beta(2)-glycoprotein I ELISA assay: the influence of different antigen preparations. THROMBOSIS AND HAEMOSTASIS 2009 vol. 101(4) pp. 789-791 CAVAZZANA A, PENGO V, TONELLO M, NOVENTA F, GROSSI C, BORGHI MO, DE MOERLOOSE P, REBER G, RUFFATTI A Fibrinogen Krakow: A novel hypo/dysfibrinogenemia mutation in fibrinogen gamma chain (Asn325IIe) affecting fibrin clot structure and function THROMBOSIS AND HAEMOSTASIS 2009 vol. 101(5) pp. 975-976 UNDAS A, ZDZIARSKA J, IWANIEC T, STEPIEN E, SKOTNICKI AB, DE MOERLOOSE P, NEERMAN-ARBEZ M Deletion of 3 residues from the C-terminus of MCFD2 affects binding to ERGIC-53 and causes combined factor V and factor VIII deficiency. BLOOD 2008 vol. 111(3) pp. 1299-1301 NYFELER B, KAMIYA, BOEHLEN F, YAMAMOTO K, KATO K, DE MOERLOOSE P, HAURI HP, NEERMAN-ARBEZ M A novel Asp344Val substitution in the fibrinogen gamma chain (fibrinogen Caen) causes dysfibrinogenemia associated with thrombosis. BLOOD COAGULATION AND FIBRINOLYSIS 2008 vol. 19(7) pp. 697-699 ROBERT-EBADI H, LE QUERREC A, DE MOERLOOSE P, GANDON-LALOUM S, BOREL DERLON A, NEERMAN-ARBEZ M Treatment of congenital fibrinogen disorders. EXPERT OPINION ON BIOLOGICAL THERAPY 2008 vol. 8(7) pp. 979-992 DE MOERLOOSE P, NEERMAN-ARBEZ M Endothelial cell activation by immunoglobulins from patients with immune thrombocytopenic purpura or with antiphospholipid syndrome. HAEMATOLOGIA 2008 vol. 93(4) pp. 635-636 DUNOYER-GEINDRE S, BOEHLEN F, FAVIER R, WAHL D, MUSIAL J, KORTE W, SATTA N, KRUITHOF EGBERT, DE MOERLOOSE P A survey of adherence to haemophilia therapy in six European countries: results and recommendations. HAEMOPHILIA 2008 vol. 14(5) pp. 931-938 DE MOERLOOSE P, URBANCIK W, VAN DEN BERG HM, RICHARDS M Molecular analysis of F8 in Lebanese haemophilia A patients: novel mutations and phenotype-genotype correlation. HAEMOPHILIA 2008 vol. 14(4) pp. 709-716 DJAMBAS KHAYAT C, SALEM N, CHOUERY E, CORBANI S, MOIX I, NICOLAS I, MORRIS M, DE MOERLOOSE P, MEGARBANE A Rare bleeding disorders. HAEMOPHILIA 2008 vol. 14 pp. 202-210 PEYVANDI F, CATTANEO M, INBAL A, DE MOERLOOSE P, SPREAFICO M Richards M HAEMOPHILIA 2008 vol. 14(4) pp. 709-716 DJAMBAS KHAYAT C, SALEM N, CHOUERY E, CORBANI S, MOIX I, NICOLAS E, MORRIS MA, DE MOERLOOSE P, MÉGARBANÉ A D-Dimer for venous thromboembolism diagnosis: 20 years later. JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2008 vol. 6(7) pp. 1059-1071 RIGHINI M, PERRIER A, DE MOERLOOSE P, BOUNAMEAUX H Invitation to a debate on the serological criteria that define the antiphospholipid syndrome. JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2008 vol. 6(2) pp. 399-401 GALLI M, REBER G, DE MOERLOOSE P, DE GROOT PG Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2008 vol. 6(3) pp. 444-450 RENY JL, DE MOERLOOSE P, DAUZAT M, FONTANA P Induction of TLR2 expression by inflammatory stimuli is required for endothelial cell responses to lipopeptides. MOLECULAR IMMUNOLOGY 2008 vol. 46(1) pp. 145-157 SATTA N, KRUITHOF EK, REBER G, DE MOERLOOSE P Technical aspects in laboratory testing for antiphospholipid antibodies: is standardization an impossible dream? SEMINARS IN THROMBOSIS AND HEMOSTASIS 2008 vol. 34(4) pp. 340-346 REBER G, BOEHLEN F, DE MOERLOOSE P A multicenter evaluation of a new quantitative highly sensitive D-dimer assay for exclusion of venous thromboembolism. THROMBOSIS AND HAEMOSTASIS 2008 vol. 100(3) pp. 505-512 DE MOERLOOSE P, PALARETI G, AGUILAR C, LEGNANI C, REBER G, PEETZ D Aspirin response variability assessed with the PFA-100 device. THROMBOSIS AND HAEMOSTASIS 2008 vol. 99(5) pp. 968-969 RENY JL, QUÉRÉ I, DE MOERLOOSE P, FONTANA P Assessing aspirin responsiveness using the Verify Now Aspirin assay. THROMBOSIS RESEARCH 2008 vol. 121(4) pp. 581-582 FONTANA P, REBER G, DE MOERLOOSE P Preventing and treating bleeding complications: new insights into therapeutic options. THROMBOSIS RESEARCH 2008 vol. 122 pp. 1-2 DE MOERLOOSE P, NEGRIER C An analysis of experimental conditions influencing the anti-beta2-glycoprotein I ELISA assay results ANNALS OF THE NEW YORK ACADEMY OF SCIENCES 2007 vol. 1109 pp. 484-492 CAVAZZANA A, RUFFATTI A, TONELLO M, BORTOLATI M, DE MOERLOOSE P, REBER G The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies BLOOD 2007 vol. 109 pp. 1507-1514 SATTA N, DUNOYER-GEINDRE S, REBER G, FISH RJ, BOEHLEN F, KRUITHOF EKO, DE MOERLOOSE P Platelet refractoriness due to combined anti-HLA and anti-HPA-5a alloantibodies: clinical management during myeloablative allogeneic HSCT and development of a quantitative MAIPA assay BRITISH JOURNAL OF HAEMATOLOGY 2007 vol. 139 pp. 159-161 ARBER C, BERTRAND G, HALTER J, BOEHLEN F, KAPLAN C, GRATWOHL A Heparin-induced thrombocytopenia associated with interleukin-8-dependent platelet activation in a patient with antiphospholipid syndrome EUROPEAN JOURNAL OF HAEMATOLOGY 2007 vol. 79 pp. 550-553 BOUNAMEAUX C, BOEHLEN F, MEMBRE A, GENNE D, POUPLARD C, REGNAULT V, DE MOERLOOSE P Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data HAEMOPHILIA 2007 vol. 13 pp. 473-479 RICHARDS M, ALTISENT C, BATOROVA A, CHAMBOST H, DOLAN G, DE MOERLOOSE P, FRAGA M, HERMANS C, KARAFOULIDOU A, KLAMROTH R, LASSILA R, ROTHSCHILD C Mutations in the fibrinogen gene cluster accounting for congenital afibrinogenemia: An update and report of 10 novel mutations HUMAN MUTATION 2007 vol. 28 pp. 540-553 NEERMAN-ARBEZ, M, DE MOERLOOSE, P Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2007 vol. 5 pp. 2153-2155 FONTANA P, HULOT JS, DE MOERLOOSE P, GAUSSEM P Performance of the AxSYM (R) D-dimer assay for the exclusion of pulmonary embolism JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2007 vol. 5 pp. 2304-2305 REBER G, BOEHLEN F, BOUNAMEAUX H, DE MOERLOOSE P Inherited thrombophilia in arterial disease: A selective review SEMINARS IN HEMATOLOGY 2007 vol. 44 pp. 106-113 DE MOERLOOSE P, BOEHLEN F Immunization of LDL receptor-deficient mice with beta(2)-glycoprotein 1 or human serum albumin induces a more inflammatory phenotype in atherosclerotic plaques THROMBOSIS AND HAEMOSTASIS 2007 vol. 97 pp. 129-138 DUNOYER-GEINDRE S, KWAK BR, PELLI G, ROTH I, SATTA N, FISH RJ, REBER G, MACH F, KRUITHOF EKO, DE MOERLOOSE P Management of venous thromboembolism CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE 2006 vol. 53(6 Suppl) pp. 80-88 DE MOERLOOSE P, SAMAMA CM, MOTTE S Minimizing perioperative blood loss and transfusions in children CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE 2006 vol. 53 pp. 59-67 GUAY J, DE MOERLOOSE P, LASNE D Point of care management of heparin administration after heart surgery - A randomized, controlled trial INTENSIVE CARE MEDICINE 2006 vol. 32 pp. 1357-1364 MERLANI PG, CHENAUD C, COTTINI S, REBER G, GARNERIN P, DE MOERLOOSE P, RICOU B Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2006 vol. 4 pp. 813-819 FONTANA P, NOLLI S, REBER G, DE MOERLOOSE P A model for the harmonisation of test results of different quantitative D-dimer methods THROMBOSIS AND HAEMOSTASIS 2006 vol. 95 pp. 567-572 MEIJER P, HAVERKATE F, KLUFT C, DE MOERLOOSE P, VERBRUGGEN B, SPANNAGL M Combined factorV-factorVIII deficiency (F5F8D): Compound heterozygosity for two novel truncating mutations in LMANI in a consanguineous patient THROMBOSIS AND HAEMOSTASIS 2006 vol. 95 pp. 893-895 FARAH RA, DE MOERLOOSE P, BOUCHARDY I, MORRIS MA, BARAKAT W, SAYAD AE, NEERMAN-ARBEZ M Discrepancy between capillary and venous International Normalised Ratio (INR) in a patient on vitamin-K antagonist: Potentially serious clinical consequences THROMBOSIS AND HAEMOSTASIS 2006 vol. 96 pp. 688-689 ABRAMOWSKI SW, BOEHLEN F, REBER G, DE MOERLOOSE P Extensive thromboembolic event as initial presentation of monoclonal gammopathy of undetermined significance THROMBOSIS AND HAEMOSTASIS 2006 vol. 96 pp. 93-94 RIGHINI M, BOEHLEN F, GUEDDI S, LE GAL G, DE MOERLOOSE P Massive transfusion and coagulopathy: pathophysiology and implications for clinical management CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE 2004 vol. 51 pp. 293-310 HARDY JF, DE MOERLOOSE PHILIPPE, SAMAMA M End-stage liver disease in person with hemophilia and transfusion-associated infections BLOOD 2002 vol. 100 pp. 1584-1589 GOEDERT J, EYSTER E, LEDERMAN M, MANDALAKI T, DE MOERLOOSE P, WHITE GC, ANGIOLILLO AL, LUBAN NLC, SHERMAN KE, MANCO-JOHNSON M, PREISS L, LEISSINGER C, KESSLER CM, COHEN AR, DIMICHELE D, HILGARTNER MW, ALEDORT LM, KRONER BL, ROSENBERG PS, HATZAKIS A Inherited factor VII deficiency and surgery : clinical data are the best criteria to predict the risk of bleeding BRITISH JOURNAL OF HAEMATOLOGY 2002 vol. 117 pp. 172-175 GIANSILY-BLAIZOT M, BIRON-ANDREANI C, AGUILAR-MARTINEZ P, DE MOERLOOSE P, BRIQUEL ME, GOUDEMAND J, STIELTJES N, BARROT C, CHAMBOST H, DURIN A, GAY V, PEYNET J, POYMAYOU K, SCHVED JF Two new antithrombotic agents (fondaparinux and ximelagatran) and their implications in anesthesia CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE 2002 vol. 49 pp. 5-10 DE MOERLOOSE P, BOEHLEN F Aerosolized iloprost induces a mild but sustained inhibition of platelet aggregation EUROPEAN RESPIRATORY JOURNAL 2002 vol. 19 pp. 518-524 BEGHETTI M, REBER G, DE MOERLOOSE P, VADAS L, CHIAPPE A, SPAHR-SCHOPFER I, RIMENSBERGER PC Measurement of red blood cell methylfolate LANCET 2002 vol. 360 pp. 1021-1022 QUERE I, ZITTOUN J, GRIS JC, JANBON C, DE MOERLOOSE P Red blood cell methylfolate and plasma homocysteine as risk factors for venous thromboembolism: a matched case-control study LANCET 2002 vol. 359 pp. 747-752 QUÉRÉ I, PERNEGER TV, ZITTOUN J, BELLET H, GRIS JC, DAURES JP, SCHVED JF, MERCIER E, LAROCHE JP, DAUZAT M, BOUNAMEAUX H, JANBON C, DE MOERLOOSE P Pelvic haemophilic pseudotumor: management of a patient with high level of inhibitors SKELETAL RADIOLOGY 2002 vol. 31 pp. 550-553 KELLER A, TERRIER F, SCHNEIDER PA, BIANCHI S, HOWARTH N, DE MOERLOOSE P Inter-variability of anti-b2glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group. THROMBOSIS AND HAEMOSTASIS 2002 vol. 88 pp. 66-73 REBER G, SHOESBOE I, TINCANI A, SANMARCO M, KVEDER T, DE MOERLOOSE P, BOFFA MC, ARVIEUX J NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies THROMBOSIS AND HAEMOSTASIS 2002 vol. 88 pp. 851-857 DUNOYER-GEINDRE S, DE MOERLOOSE P, GALVE-DE ROCHEMONTEIX B, REBER G, KRUITHOF EK Evaluation of Advanced D-dimer assay for the exclusion of venous thromboembolism THROMBOSIS RESEARCH 2002 vol. 107 pp. 197-200 REBER G, BOUNAMEAUX H, PERRIER A, DE MOERLOOSE P Point of care and central laboratory determinations of the aPTT are not interchangeable in surgical intensive care patients CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE 2001 vol. 48 pp. 1155-1160 FERRING M, REBER G, DE MOERLOOSE P, MERLANI P, DIBY M, RICOU B Research's domains